{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:53Z","timestamp":1789644893215,"version":"4.0.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dong-A University Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chimeric antigen receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory B-cell malignancies. Despite therapeutic success, infectious complications remain a major contributor to non-relapsed morbidity and mortality. The risk of infection reflects a prolonged and multifactorial state of immunosuppression resulting from lymphodepleting chemotherapy, treatment-related cytopenia, sustained CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell lymphopenia, B-cell aplasia with hypogammaglobulinemia, and the use of corticosteroids or cytokine-directed therapies for the management of immune effector cell-associated toxicities (i.e., cytokine-release syndrome and immune effector cell\u2013associated neurotoxicity). The spectrum of infections has evolved over time. Bacterial infections are observed most frequently in the early post-infusion period, whereas viral and opportunistic infections become more prominent later, particularly in patients with delayed immune recovery. Infection risk is also influenced by the underlying malignancy, prior exposure to treatment, and the type of CAR T-cell product used. For example, BCMA-directed CAR T-cell therapy has been associated with a higher infection burden, likely related to profound plasma cell depletion and sustained impairment of humoral immunity. Preventing infections in this setting requires a structured and individualized approach. Common strategies include antiviral and\n                    <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                    pneumonia prophylaxis, the selective use of antibacterial and antifungal prophylaxis during periods of severe or prolonged cytopenia, immunoglobulin replacement in patients with clinically significant hypogammaglobulinemia, and vaccination schedules guided by immune recovery. Therefore, coordinated and risk-adapted prevention is essential to minimize infectious complications and to improve long-term outcomes after CAR-T cell therapy. This review summarizes the current evidence and major recommendations of international guidelines to provide an updated overview of infection mechanisms, risk stratification, and preventive strategies for patients receiving CAR T-cell therapy.\n                  <\/jats:p>","DOI":"10.1007\/s44313-026-00145-2","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:56:56Z","timestamp":1781161016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention"],"prefix":"10.1007","volume":"61","author":[{"given":"Eunseuk","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jae","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"145_CR1","unstructured":"B-Cell Lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 1.2026."},{"issue":"9","key":"145_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"22","key":"145_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"20","key":"145_CR4","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1182\/bloodadvances.2020003848","volume":"5","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149\u201355.","journal-title":"Blood Adv"},{"issue":"12","key":"145_CR5","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-023-02042-4","volume":"37","author":"VS A","year":"2023","unstructured":"A VS, et al. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Leukemia. 2023;37(12):2346\u201355.","journal-title":"Leukemia"},{"issue":"23","key":"145_CR6","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood.2024024995","volume":"144","author":"N Puig","year":"2024","unstructured":"Puig N, et al. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma. Blood. 2024;144(23):2432\u20138.","journal-title":"Blood"},{"issue":"6","key":"145_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"145_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","volume":"22","author":"TJ Bock","year":"2025","unstructured":"Bock TJ, et al. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat Rev Clin Oncol. 2025;22(4):241\u201361.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"145_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience. Br J Haematol. 2022;198(3):492\u2013502.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"145_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14148","volume":"25","author":"MT Czapka","year":"2023","unstructured":"Czapka MT, Riedell PA, Pisano JC. Infectious complications of CAR T-cell therapy: a longitudinal risk model. Transpl Infect Dis. 2023;25(Suppl 1):e14148.","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"145_CR11","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667\u201378.","journal-title":"Nat Med"},{"issue":"21","key":"145_CR12","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","volume":"7","author":"J Lemoine","year":"2023","unstructured":"Lemoine J, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7(21):6589\u201398.","journal-title":"Blood Adv"},{"key":"145_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1252811","volume":"14","author":"O Penack","year":"2023","unstructured":"Penack O, et al. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811.","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"145_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14157","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, et al. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis. 2023;25(Suppl 1):e14157.","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"145_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","volume":"33","author":"G Haidar","year":"2020","unstructured":"Haidar G, Garner W, Hill JA. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Curr Opin Infect Dis. 2020;33(6):449\u201357.","journal-title":"Curr Opin Infect Dis"},{"key":"145_CR16","unstructured":"Prevention and Treatment of Cancer-Related Infections. NCCN(National Comprehensive Cancer Network). Version 2.2025-January 22, 2026."},{"key":"145_CR17","unstructured":"Management of CAR T-Cell and Lymphocyte Engager-Related Toxicities. NCCN Clinical Practice Guidelines in Oncology. Version 2.2026-November 11, 2025."},{"issue":"11","key":"145_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","volume":"20","author":"G Telli Dizman","year":"2022","unstructured":"Telli Dizman G, Aguado JM, Fernandez-Ruiz M. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20(11):1455\u201376.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"21","key":"145_CR19","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","volume":"9","author":"K Wudhikarn","year":"2025","unstructured":"Wudhikarn K, et al. Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025;9(21):5460\u201372.","journal-title":"Blood Adv"},{"issue":"20","key":"145_CR20","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"issue":"24","key":"145_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138(24):2499\u2013513.","journal-title":"Blood"},{"issue":"1","key":"145_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2023000472","volume":"2023","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program. 2023;2023(1):198\u2013208.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"145_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377.","journal-title":"Blood"},{"key":"145_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215920","volume":"550","author":"X Si","year":"2022","unstructured":"Si X, et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 2022;550:215920.","journal-title":"Cancer Lett"},{"issue":"2","key":"145_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cmi.2025.10.005","volume":"32","author":"A Bouvier","year":"2026","unstructured":"Bouvier A, et al. Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d\u2019Enregistrement et Suivi des patients traites par CAR-T cells) registry. Clin Microbiol Infect. 2026;32(2):277\u201384.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"145_CR26","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","volume":"25","author":"P Ljungman","year":"2025","unstructured":"Ljungman P, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25(8):e451\u201362.","journal-title":"Lancet Infect Dis"},{"key":"145_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/v17010133","author":"J Sassine","year":"2025","unstructured":"Sassine J, Siegrist EA, Chemaly RF. Herpesvirus infections after Chimeric Antigen Receptor T-Cell Therapy and bispecific antibodies: a review. Viruses. 2025. https:\/\/doi.org\/10.3390\/v17010133.","journal-title":"Viruses"},{"key":"145_CR28","unstructured":"Hematopoietic Growth Factors. NCCN Clinical Practice Guidelines in Oncology. Version 3.2026."},{"issue":"4","key":"145_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtct.2024.01.073","volume":"30","author":"N Nakamura","year":"2024","unstructured":"Nakamura N, et al. Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T Cell therapy: KyoTox A-Score, a novel prediction model. Transplant Cell Ther. 2024;30(4):404\u201314.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"145_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/hematology.2024000534","volume":"2024","author":"MR Bishop","year":"2024","unstructured":"Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology Am Soc Hematol Educ Program. 2024;2024(1):109\u201315.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"145_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","volume":"15","author":"E Kampouri","year":"2022","unstructured":"Kampouri E, et al. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022;15(4):305\u201320.","journal-title":"Expert Rev Hematol"},{"key":"145_CR32","unstructured":"Multiple Myeloma. NCCN Clinical Practice Guidelines in Oncology. Version 5.2026-January 9.2026."},{"issue":"35","key":"145_CR33","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"issue":"13","key":"145_CR34","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","volume":"9","author":"A Riedel","year":"2025","unstructured":"Riedel A, et al. Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. Blood Adv. 2025;9(13):3149\u201358.","journal-title":"Blood Adv"},{"key":"145_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104134","volume":"192","author":"GK Reynolds","year":"2023","unstructured":"Reynolds GK, et al. Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;192:104134.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"145_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925\u201335.","journal-title":"Blood"},{"issue":"8","key":"145_CR37","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","volume":"12","author":"N van de Donk","year":"2025","unstructured":"van de Donk N, et al. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. Lancet Haematol. 2025;12(8):e635\u201349.","journal-title":"Lancet Haematol"},{"issue":"23","key":"145_CR38","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(23):5290\u20139.","journal-title":"Blood Adv"},{"issue":"6","key":"145_CR39","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361.","journal-title":"Lancet Haematol"},{"key":"145_CR40","doi-asserted-by":"crossref","unstructured":"Josyula S, et al. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. Transplant Cell Ther, 2022;28(6):304. e1\u2013304 e9.","DOI":"10.1016\/j.jtct.2022.03.005"},{"issue":"2","key":"145_CR41","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10(2):460\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"145_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1200\/JCO-25-00507","volume":"44","author":"RT Maziarz","year":"2026","unstructured":"Maziarz RT, et al. Five-year analysis of the JULIET trial of Tisagenlecleucel in patients with relapsed\/refractory large B-Cell lymphoma. J Clin Oncol. 2026;44(2):86\u201391.","journal-title":"J Clin Oncol"},{"issue":"19","key":"145_CR43","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"1","key":"145_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","volume":"13","author":"Y Yang","year":"2024","unstructured":"Yang Y, et al. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13(1):110.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"145_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T Cells. Clin Infect Dis. 2018;67(4):533\u201340.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"145_CR46","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","volume":"12","author":"PJ Brockelmann","year":"2025","unstructured":"Brockelmann PJ, et al. Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies. Lancet Haematol. 2025;12(6):e470\u201381.","journal-title":"Lancet Haematol"},{"key":"145_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1398078","volume":"14","author":"S Arya","year":"2024","unstructured":"Arya S, Shahid Z. Overview of infectious complications among CAR T- cell therapy recipients. Front Oncol. 2024;14:1398078.","journal-title":"Front Oncol"},{"issue":"14","key":"145_CR48","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"20","key":"145_CR49","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139.","journal-title":"Blood"},{"issue":"6","key":"145_CR50","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, et al. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11(6):e459\u201370.","journal-title":"Lancet Haematol"},{"issue":"7","key":"145_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","volume":"39","author":"L Pagano","year":"2025","unstructured":"Pagano L, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025;39(7):1547\u201357.","journal-title":"Leukemia"},{"issue":"3","key":"145_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Lievin","year":"2022","unstructured":"Lievin R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 2022;57(3):431\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"145_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"3","key":"145_CR54","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","volume":"8","author":"C Gudiol","year":"2021","unstructured":"Gudiol C, et al. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021;8(3):e216\u201328.","journal-title":"Lancet Haematol"},{"issue":"8","key":"145_CR55","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813\u201326.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"145_CR56","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60(11):1499\u2013525.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"145_CR57","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","volume":"30","author":"Z Shahid","year":"2024","unstructured":"Shahid Z, et al. Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024;30(10):955\u201369.","journal-title":"Transplant Cell Ther"},{"issue":"30","key":"145_CR58","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043\u201354.","journal-title":"J Clin Oncol"},{"issue":"1","key":"145_CR59","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S1473-3099(25)00311-1","volume":"26","author":"C Liu","year":"2026","unstructured":"Liu C, et al. Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship. Lancet Infect Dis. 2026;26(1):e30\u201348.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"145_CR60","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1080\/10428194.2023.2243355","volume":"64","author":"JS Al-Ramahi","year":"2023","unstructured":"Al-Ramahi JS, et al. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. Leuk Lymphoma. 2023;64(12):1981\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"145_CR61","doi-asserted-by":"publisher","first-page":"1108 e1","DOI":"10.1016\/j.jtct.2024.08.010","volume":"30","author":"EA Rosen","year":"2024","unstructured":"Rosen EA, et al. COVID-19 outcomes among hematopoietic cell transplant and chimeric antigen receptor T-cell recipients in the era of SARS-CoV-2 Omicron variants and COVID-19 therapeutics. Transplant Cell Ther. 2024;30(11):1108 e1-1108 e11.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"145_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/hematology.2024000535","volume":"2024","author":"N Tabbara","year":"2024","unstructured":"Tabbara N, Dioverti-Prono MV, Jain T. Mitigating and managing infection risk in adults treated with CAR T-cell therapy. Hematology Am Soc Hematol Educ Program. 2024;2024(1):116\u201325.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"145_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1272798","volume":"14","author":"E Pennese","year":"2023","unstructured":"Pennese E, et al. Case report: invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis. Front Immunol. 2023;14:1272798.","journal-title":"Front Immunol"},{"issue":"3","key":"145_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","volume":"27","author":"SS Dadwal","year":"2021","unstructured":"Dadwal SS, et al. American Society of Transplantation and Cellular Therapy Series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients. Transplant Cell Ther. 2021;27(3):201\u201311.","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"145_CR65","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(14):1699\u2013721.","journal-title":"J Clin Oncol"},{"key":"145_CR66","unstructured":"Survivorship. NCCN Clinical Practice Guidelines in Oncology. Version 3.2025 - February 2, 2026."},{"issue":"1","key":"145_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","volume":"15","author":"S Einarsdottir","year":"2025","unstructured":"Einarsdottir S, et al. Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies. Blood Cancer J. 2025;15(1):114.","journal-title":"Blood Cancer J"},{"key":"145_CR68","doi-asserted-by":"crossref","unstructured":"Aleissa MM, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients. Transplant Cell Ther. 2023;29(6):398. e1\u2013398 e5.","DOI":"10.1016\/j.jtct.2023.03.005"},{"key":"145_CR69","doi-asserted-by":"crossref","unstructured":"Lee D, et al.Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplant Cell Ther. 2023;29(4):277. e1\u2013277 e9.","DOI":"10.1016\/j.jtct.2022.08.011"},{"issue":"1","key":"145_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","volume":"29","author":"F Khawaja","year":"2023","unstructured":"Khawaja F, et al. Frequently asked questions on Coronavirus Disease 2019 vaccination for hematopoietic cell transplantation and chimeric antigen receptor T-Cell recipients from the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transplant Cell Ther. 2023;29(1):10\u20138.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"145_CR71","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cid\/ciae291","volume":"79","author":"JA Hill","year":"2024","unstructured":"Hill JA, et al. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-Cell therapy: A prospective, multicenter, observational study. Clin Infect Dis. 2024;79(2):542\u201354.","journal-title":"Clin Infect Dis"},{"key":"145_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143527","author":"S Gossi","year":"2022","unstructured":"Gossi S, et al. Humoral responses to repetitive doses of COVID-19 mRNA vaccines in patients with CAR-T-Cell Therapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14143527.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"145_CR73","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jtct.2025.02.019","volume":"31","author":"H Kinoshita","year":"2025","unstructured":"Kinoshita H, et al. T Cell immune response to Influenza Vaccination when administered prior to and following autologous Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther. 2025;31(5):327\u201338.","journal-title":"Transplant Cell Ther"},{"key":"145_CR74","unstructured":"Pediatric Acute Lymphoblastic Leukemia. NCCN Clinical Practice Guidelines in Oncology. Version 1.2026."},{"issue":"5","key":"145_CR75","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149(5):1525\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"145_CR76","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","volume":"14","author":"A Wonnaparhown","year":"2024","unstructured":"Wonnaparhown A, et al. IgG replacement in multiple myeloma. Blood Cancer J. 2024;14(1):124.","journal-title":"Blood Cancer J"},{"issue":"6","key":"145_CR77","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255\u201369.","journal-title":"Lancet Oncol"},{"issue":"2","key":"145_CR78","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali FS, et al. AGA Clinical Practice Guideline on the prevention and treatment of Hepatitis B Virus reactivation in at-risk individuals. Gastroenterology. 2025;168(2):267\u201384.","journal-title":"Gastroenterology"},{"issue":"5","key":"145_CR79","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3026(25)00049-3","volume":"12","author":"M Mikulska","year":"2025","unstructured":"Mikulska M, et al. Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9). Lancet Haematol. 2025;12(5):e389\u201399.","journal-title":"Lancet Haematol"},{"issue":"2","key":"145_CR80","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49(2):215\u201331.","journal-title":"Infection"},{"key":"145_CR81","doi-asserted-by":"crossref","unstructured":"Infante MS, et al. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024;30(1):116. e1\u2013116 e12.","DOI":"10.1016\/j.jtct.2023.09.027"},{"key":"145_CR82","doi-asserted-by":"crossref","unstructured":"Mushtaq MU, et al. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplant Cell Ther 2021;27(9):796. e1\u2013796 e7.","DOI":"10.1016\/j.jtct.2021.07.005"},{"issue":"9","key":"145_CR83","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/14787210.2022.2101448","volume":"20","author":"D Luque-Paz","year":"2022","unstructured":"Luque-Paz D, et al. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. Expert Rev Anti Infect Ther. 2022;20(9):1155\u201362.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"145_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14144","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, Hill JA, Dioverti V. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy. Transpl Infect Dis. 2023;25(Suppl 1):e14144.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"145_CR85","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1016\/S1473-3099(23)00563-7","volume":"24","author":"KPL Cheok","year":"2024","unstructured":"Cheok KPL, et al. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature. Lancet Infect Dis. 2024;24(4):e256\u201365.","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"145_CR86","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","volume":"8","author":"RY Lin","year":"2024","unstructured":"Lin RY, et al. Incidence and outcomes of Cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024;8(14):3813\u201322.","journal-title":"Blood Adv"},{"issue":"12","key":"145_CR87","doi-asserted-by":"publisher","first-page":"851 e1","DOI":"10.1016\/j.jtct.2022.09.007","volume":"28","author":"E Marquez-Algaba","year":"2022","unstructured":"Marquez-Algaba E, et al. Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2022;28(12):851 e1-851 e8.","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"145_CR88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12185-025-04023-y","volume":"122","author":"K Hayashino","year":"2025","unstructured":"Hayashino K, et al. Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Int J Hematol. 2025;122(5):689\u201399.","journal-title":"Int J Hematol"},{"issue":"12","key":"145_CR89","doi-asserted-by":"publisher","first-page":"e1121","DOI":"10.1016\/j.clml.2025.08.014","volume":"25","author":"MA Khan","year":"2025","unstructured":"Khan MA, et al. Predicators and outcomes of Cytomegalovirus reactivation in chimeric antigen receptor T-cell therapy: A systematic review. Clin Lymphoma Myeloma Leuk. 2025;25(12):e1121\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00145-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00145-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00145-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:03:02Z","timestamp":1781168582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00145-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00145-2","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}